Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.

Hamilton A, Thisted L, Ougaard M, Hahn M, Andersen K, Perens J, Augustin R, Bajrami B, Rist W, Christensen M, Hansen HH, Klein T

Diabetes, obesity & metabolism1 Oct 2026

PMID42823075DOI10.1111/dom.71387PepBankPUB-42823075

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide reduced body weight compared with vehicle.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide lowered body weight compared with vehicle.
Peptide
Survodutide
Outcome
DecreaseBody weight
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Body weight · Metabolic and weight
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Compared to vehicle controls, survodutide reduced body weight
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307501
02AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide reduced hyperglycemia compared with vehicle.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide lowered high blood sugar compared with vehicle.
Peptide
Survodutide
Outcome
DecreaseHyperglycemia
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Compared to vehicle controls, survodutide reduced body weight, hyperglycemia
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307502
03AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide reduced HbA1c levels compared with vehicle.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide lowered HbA1c compared with vehicle.
Peptide
Survodutide
Outcome
DecreaseHbA1c
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Compared to vehicle controls, survodutide reduced body weight, hyperglycemia, and HbA1c levels
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307503
04AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide was accompanied by improved hyperinsulinemia compared with vehicle.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide improved high insulin levels compared with vehicle.
Peptide
Survodutide
Outcome
DecreaseHyperinsulinemia
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
improved hyperinsulinemia and β-cell islet volume distribution.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307504
05AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide was accompanied by improved beta-cell islet volume distribution compared with vehicle.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide improved the size distribution of insulin-making islets compared with vehicle.
Peptide
Survodutide
Outcome
Direction not reportedBeta-cell islet volume distribution
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
improved hyperinsulinemia and β-cell islet volume distribution.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307505
06AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide gave substantial benefits on advanced albuminuria.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide gave clear benefits on protein loss in the urine.
Peptide
Survodutide
Outcome
Direction not reportedAdvanced albuminuria
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Kidney function · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307506
07AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide gave substantial benefits on severe glomerulosclerosis.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide gave clear benefits on kidney filter scarring.
Peptide
Survodutide
Outcome
Direction not reportedGlomerulosclerosis
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Kidney function · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307507
08AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide gave substantial benefits on kidney hypertrophy.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide gave clear benefits on kidney enlargement.
Peptide
Survodutide
Outcome
Direction not reportedKidney hypertrophy (histology)
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Kidney function · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307508
09AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide gave substantial benefits on kidney inflammation.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide gave clear benefits on kidney inflammation.
Peptide
Survodutide
Outcome
Direction not reportedKidney inflammation
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307509
10AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, 3D whole-kidney imaging showed that survodutide significantly reduced kidney and glomerular hypertrophy.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide reduced kidney and kidney filter enlargement on 3D imaging.
Peptide
Survodutide
Outcome
DecreaseKidney and glomerular hypertrophy (3D imaging)
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Kidney function · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
3D whole-kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307510
11AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, 3D whole-kidney imaging showed that survodutide increased glomerular density.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide increased the density of kidney filters on 3D imaging.
Peptide
Survodutide
Outcome
IncreaseGlomerular density
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Kidney function · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
3D whole-kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307511
12AnimalAnimal study (in vivo)Efficacy outcome
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, 3D whole-kidney imaging showed that survodutide improved glomerular sphericity.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide improved the shape of kidney filters on 3D imaging.
Peptide
Survodutide
Outcome
Direction not reportedGlomerular sphericity
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Kidney function · Kidney and urinary
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
3D whole-kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307512
13AnimalAnimal study (in vivo)Mechanism
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide reduced liver weight.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide lowered liver weight.
Peptide
Survodutide
Outcome
DecreaseLiver weight
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Liver fat and liver function · Liver
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Survodutide reduced liver weight and plasma amino acid levels, including alanine, confirming hepatic glucagon receptor activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307513
14AnimalAnimal study (in vivo)Mechanism
In db/db UNx-ReninAAV mice with advanced diabetic kidney disease, survodutide reduced plasma amino acid levels, including alanine, which confirmed hepatic glucagon receptor activation.
In plain wordsIn mice with advanced diabetic kidney disease, survodutide lowered blood amino acid levels, a sign that it acted on glucagon receptors in the liver.
Peptide
Survodutide
Outcome
DecreasePlasma amino acids including alanine
Study
mousen: not reported in source
db/db UNx-ReninAAV mice (advanced diabetic kidney disease)
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Liver
Studied dose
7.5 nmol/kg once daily · subcutaneous · 10 weeksAs given in this study (mouse).
Source sentences
Summary
Survodutide reduced liver weight and plasma amino acid levels, including alanine, confirming hepatic glucagon receptor activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks.
Report a problemFND-4282307514

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.